Study Results from Brigham and Women's Hospital in the Area of Colon Cancer Reported [Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition In pik3ca-activated Stage Iii Colon Cancer: Calgb/swog 80702 (Alliance)].

A study conducted at Brigham and Women's Hospital in Boston, Massachusetts, explored the use of cyclooxygenase 2 (COX-2) inhibitors in the treatment of stage III colon cancer. The study found that patients with PIK3CA gain-of-function mutations who were treated with the COX-2 inhibitor celecoxib had improved disease-free survival and overall survival compared to patients without these mutations. While the overall results did not show a statistically significant improvement in disease-free survival, the findings suggest that selective usage of COX-2 inhibitors may be beneficial for certain patients with stage III colon cancer. The study was supported by the NIH National Cancer Institute. [Extracted from the article]